​

Olema Pharmaceuticals (OLMA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

OLMA Stock Forecast

Olema Pharmaceuticals stock forecast is as follows: an average price target of $27.00 (represents a 342.62% upside from OLMA’s last price of $6.10) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

OLMA Price Target

The average price target for Olema Pharmaceuticals (OLMA) is $27.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $27.00 to $27.00. This represents a potential 342.62% upside from OLMA's last price of $6.10.

OLMA Analyst Ratings

Buy

According to 3 Wall Street analysts, Olema Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for OLMA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Olema Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024Richard LawGoldman Sachs$27.00$11.91126.70%342.62%
May 16, 2024Emily BodnarH.C. Wainwright$30.00$9.85204.57%391.80%
Apr 02, 2024Richard LawGoldman Sachs$24.00$10.89120.39%293.44%

The latest Olema Pharmaceuticals stock forecast, released on Oct 24, 2024 by Richard Law from Goldman Sachs, set a price target of $27.00, which represents a 126.70% increase from the stock price at the time of the forecast ($11.91), and a 342.62% increase from OLMA last price ($6.10).

Olema Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts-13
Avg Price Target-$27.00$27.00
Last Closing Price$6.10$6.10$6.10
Upside/Downside-100.00%342.62%342.62%

In the current month, the average price target of Olema Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Olema Pharmaceuticals's last price of $6.10. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024H.C. WainwrightBuyBuyHold
Oct 24, 2024Goldman SachsBuyBuyHold
Jun 04, 2024OppenheimerOutperformOutperformHold
May 16, 2024H.C. WainwrightBuyBuyHold
Apr 02, 2024Goldman SachsBuyInitialise
Jun 09, 2022H.C. WainwrightBuyUpgrade

Olema Pharmaceuticals's last stock rating was published by H.C. Wainwright on Oct 24, 2024. The company gave OLMA a "Buy" rating, the same as its previous rate.

Olema Pharmaceuticals Financial Forecast

Olema Pharmaceuticals Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Olema Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. OLMA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Olema Pharmaceuticals EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict OLMA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Olema Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Olema Pharmaceuticals Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-39.65M$-36.19M$-34.39M$-41.97M$-46.57M$-40.66M$-38.22M$-35.65M$-36.41M$-32.70M$-30.57M
High Forecast$-39.65M$-36.19M$-34.39M$-41.97M$-46.57M$-40.66M$-38.22M$-33.89M$141.60M$-32.70M$-30.57M
Low Forecast$-39.65M$-36.19M$-34.39M$-41.97M$-46.57M$-40.66M$-38.22M$-37.40M$-855.68M$-32.70M$-30.57M
Surprise %-----------

Olema Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OLMA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Olema Pharmaceuticals SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Olema Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to OLMA last annual SG&A of $NaN (undefined).

Olema Pharmaceuticals EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.69$-0.63$-0.60$-0.73$-0.81$-0.71$-0.67$-0.62$-0.64$-0.57$-0.54
High Forecast$-0.69$-0.63$-0.60$-0.73$-0.81$-0.71$-0.67$-0.59$2.47$-0.57$-0.54
Low Forecast$-0.69$-0.63$-0.60$-0.73$-0.81$-0.71$-0.67$-0.65$-14.94$-0.57$-0.54
Surprise %-----------

According to undefined Wall Street analysts, Olema Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OLMA previous annual EPS of $NaN (undefined).

Olema Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PEPGPepGen$4.30$29.50586.05%Buy
MOLNMolecular Partners$5.25$29.00452.38%Buy
OLMAOlema Pharmaceuticals$6.14$27.00339.74%Buy
SANASana Bio$1.91$8.00318.85%Buy
LRMRLarimar Therapeutics$4.32$17.00293.52%Buy
ANTXAN2 Therapeutics$1.34$5.00273.13%Buy
CGEMCullinan Oncology$11.49$34.00195.91%Buy
FENCFennec Pharmaceuticals$6.07$15.75159.47%Buy
MLYSMineralys Therapeutics$12.35$30.00142.91%Buy
ERASErasca$2.63$6.00128.14%Buy
PHVSPharvaris$18.49$42.00127.15%Buy
ZNTLZentalis Pharmaceuticals$3.13$7.00123.64%Buy
DSGNDesign Therapeutics$6.25$9.6754.72%Buy
CNTACentessa Pharmaceuticals$17.60$23.2532.10%Buy
IRONDisc Medicine$65.00$77.6719.49%Buy

OLMA Forecast FAQ

Is Olema Pharmaceuticals a good buy?

Yes, according to 3 Wall Street analysts, Olema Pharmaceuticals (OLMA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of OLMA's total ratings.

What is OLMA's price target?

Olema Pharmaceuticals (OLMA) average price target is $27 with a range of $27 to $27, implying a 342.62% from its last price of $6.1. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Olema Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for OLMA stock, the company can go up by 342.62% (from the last price of $6.1 to the average price target of $27), up by 342.62% based on the highest stock price target, and up by 342.62% based on the lowest stock price target.

Can Olema Pharmaceuticals stock reach $9?

OLMA's average twelve months analyst stock price target of $27 supports the claim that Olema Pharmaceuticals can reach $9 in the near future.

What are Olema Pharmaceuticals's analysts' financial forecasts?

Olema Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-161M (high $-159M, low $-163M), average SG&A $0 (high $0, low $0), and average EPS is $-2.813 (high $-2.783, low $-2.844). OLMA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-152M (high $-152M, low $-152M), average SG&A $0 (high $0, low $0), and average EPS is $-2.658 (high $-2.658, low $-2.658).